NAD+ Therapy: The Science Behind the Anti-Aging Molecule
NAD+ levels decline with age. Here is what the research actually says about peptide-adjacent NAD+ therapies.
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell, essential for over 500 enzymatic reactions including those that produce cellular energy (ATP) and repair DNA. It plays a central role in processes linked to aging, and its decline with age has become one of the most researched targets in longevity medicine.
Research from the labs of David Sinclair at Harvard and Johan Auwerx at EPFL has helped establish that NAD+ levels decline by approximately 50% between ages 20 and 50, and that restoring NAD+ levels in animal models can reverse multiple hallmarks of aging including mitochondrial dysfunction, DNA damage accumulation, and cellular senescence.
NAD+ works as a cofactor for sirtuins — a family of proteins often called "longevity genes" — and PARPs, which are critical DNA repair enzymes. When NAD+ levels are adequate, sirtuins and PARPs function optimally, helping maintain genomic stability, regulate metabolism, and support cellular stress responses.
In clinical practice, NAD+ is delivered via IV infusion or subcutaneous injection. IV NAD+ produces more immediate effects — patients often report a rapid boost in energy, mental clarity, and even mood — but subcutaneous administration offers more sustainable, gradual improvements in cellular energy and cognitive function.
For telehealth patients, subcutaneous NAD+ or oral NAD+ precursors (like NMN and NR) offer the most accessible starting points. Providers like RegenX Health and Concierge MD specialize in NAD+ optimization and can guide patients through the most appropriate delivery method based on their goals and budget.
Peptides mentioned in this article: